National Pension Service Increases Position in IQVIA Holdings Inc. $IQV

National Pension Service raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 287,089 shares of the medical research company’s stock after purchasing an additional 7,903 shares during the period. National Pension Service owned approximately 0.17% of IQVIA worth $54,530,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Artisan Partners Limited Partnership bought a new position in IQVIA during the second quarter valued at approximately $515,772,000. Norges Bank purchased a new stake in shares of IQVIA in the 2nd quarter valued at $270,160,000. AQR Capital Management LLC raised its position in IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after purchasing an additional 879,701 shares during the period. Laurel Wealth Advisors LLC lifted its stake in IQVIA by 15,755.2% in the second quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after purchasing an additional 774,681 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after buying an additional 606,391 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQV stock opened at $229.93 on Monday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm has a 50-day moving average of $230.94 and a 200 day moving average of $208.89. The company has a market cap of $39.16 billion, a P/E ratio of 31.54, a PEG ratio of 2.34 and a beta of 1.37.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. UBS Group boosted their target price on IQVIA from $250.00 to $280.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Morgan Stanley increased their price objective on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Evercore ISI lifted their target price on shares of IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. Stifel Nicolaus increased their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Finally, HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $251.06.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.